Literature DB >> 15204430

Inhibition of erythropoietin activity by cyanate.

Kyung-Dae Park1, Kyo-Cheol Mun, Eun-Ju Chang, Sung-Bae Park, Hyun-Chul Kim.   

Abstract

OBJECTIVE: Increased urea concentration is a measure of advanced renal failure and the adequacy of renal replacement therapy in end-stage renal disease (ESRD). Altered biologic activity due to changes in protein structure occurs when cyanate, formed spontaneously from urea, reacts with proteins. Carbamylation results in impaired erythropoietin (EPO) activity when high concentrations of cyanate react with EPO. In this study, the activity of carbamylated EPO (C-EPO), formed at a cyanate concentration which may occur in vivo, was studied in Sprague-Dawley rats.
MATERIAL AND METHODS: The extent of carbamylation, causing loss of free amino groups, was monitored using trinitrobenzenesulfonic acid. Erythrocyte, hemoglobin, hematocrit and leukocyte levels were measured after either EPO, incubated EPO, C-EPO, physiologic saline or cyanate (1.5 microM; 0.2 ml) were injected subcutaneous twice weekly for 3 weeks in rats.
RESULTS: In vitro carbamylation of EPO was time- and concentration-dependent. C-EPO concentration increased as the duration of exposure to cyanate increased from 6 to 72 h, or as cyanate concentration increased from 15 nM to 1.5 microM. Injections of EPO caused significant increases in vivo in all erythropoietic measures. In contrast, injections of C-EPO, physiologic saline or 1.5 microM cyanate caused no change from baseline.
CONCLUSIONS: These results demonstrated diminished biologic activity in healthy rats by C-EPO formed in vitro at cyanate concentrations that may be found in vivo. C-EPO and high urea-derived cyanate levels may contribute to suboptimal erythropoietic responses to EPO therapy for chronic renal failure and ESRD, and may provide another measurement indicating inadequate dialysis.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15204430     DOI: 10.1080/00365590310006291

Source DB:  PubMed          Journal:  Scand J Urol Nephrol        ISSN: 0036-5599


  12 in total

Review 1.  Mechanisms and consequences of carbamoylation.

Authors:  Sigurd Delanghe; Joris R Delanghe; Reinhart Speeckaert; Wim Van Biesen; Marijn M Speeckaert
Journal:  Nat Rev Nephrol       Date:  2017-07-31       Impact factor: 28.314

2.  Effects of amino acids and albumin on erythropoietin carbamoylation.

Authors:  Kyubok Jin
Journal:  Clin Exp Nephrol       Date:  2012-12-11       Impact factor: 2.801

3.  Protein carbamylation is a hallmark of aging.

Authors:  Laëtitia Gorisse; Christine Pietrement; Vincent Vuiblet; Christian E H Schmelzer; Martin Köhler; Laurent Duca; Laurent Debelle; Paul Fornès; Stéphane Jaisson; Philippe Gillery
Journal:  Proc Natl Acad Sci U S A       Date:  2015-12-28       Impact factor: 11.205

Review 4.  Erythropoietin molecules to treat acute ischemic stroke: a translational dilemma!

Authors:  Paul A Lapchak
Journal:  Expert Opin Investig Drugs       Date:  2010-10       Impact factor: 6.206

5.  Glutaraldehyde erythropoietin protects kidney in ischaemia/reperfusion injury without increasing red blood cell production.

Authors:  S Chattong; J Tanamai; P Kiatsomchai; M Nakatsu; A Sereemaspun; N Pimpha; K Praditpornsilpa; R Rojanathanes; A Sethpakadee; K Tungsanga; S Eiam-Ong; K Manotham
Journal:  Br J Pharmacol       Date:  2013-01       Impact factor: 8.739

6.  Post-ischemic treatment with erythropoietin or carbamylated erythropoietin reduces infarction and improves neurological outcome in a rat model of focal cerebral ischemia.

Authors:  Y Wang; Z G Zhang; K Rhodes; M Renzi; R L Zhang; A Kapke; M Lu; C Pool; G Heavner; M Chopp
Journal:  Br J Pharmacol       Date:  2007-07-02       Impact factor: 8.739

Review 7.  Protein carbamylation and cardiovascular disease.

Authors:  Frederik H Verbrugge; W H Wilson Tang; Stanley L Hazen
Journal:  Kidney Int       Date:  2015-06-10       Impact factor: 10.612

Review 8.  Protein carbamylation in kidney disease: pathogenesis and clinical implications.

Authors:  Sahir Kalim; S Ananth Karumanchi; Ravi I Thadhani; Anders H Berg
Journal:  Am J Kidney Dis       Date:  2014-07-16       Impact factor: 8.860

9.  LDL biochemical modifications: a link between atherosclerosis and aging.

Authors:  Matilde Alique; Carlos Luna; Julia Carracedo; Rafael Ramírez
Journal:  Food Nutr Res       Date:  2015-12-03       Impact factor: 3.894

10.  Carbamylated erythropoietin attenuates cardiomyopathy via PI3K/Akt activation in rats with diabetic cardiomyopathy.

Authors:  Hongying He; Xiaoyu Qiao; Suisheng Wu
Journal:  Exp Ther Med       Date:  2013-05-31       Impact factor: 2.447

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.